Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749463 | 0.85 | TGM2 (0.47) | ALDH1A1POLBGLAKMT2ALMNA | |
| SCHEMBL3754218 | 0.83 | ALDH1A1 (0.66) | ALDH1A1POLBMAPK1KMT2AGAA | |
| SCHEMBL3755185 | 0.83 | ALDH1A1 (0.68) | ALDH1A1POLBKMT2AGAALMNA | |
| SCHEMBL3757356 | 0.82 | ALDH1A1 (0.67) | ALDH1A1POLBKMT2AGAALMNA | |
| SCHEMBL3755792 | 0.80 | KMT2A (0.44) | ALDH1A1POLBGLAKMT2AUSP2 | |
| SCHEMBL3761389 | 0.78 | GLA (0.44) | ALDH1A1GLAKMT2AGAALMNA | |
| SCHEMBL3761284 | 0.73 | HTT (0.58) | ALDH1A1MAPK1KMT2AUSP2GAA | |
| SCHEMBL3754201 | 0.70 | P2RX7 (0.46) | ALDH1A1MAPK1GLAKMT2AUSP2 | |
| SCHEMBL3791796 | 0.69 | HTT (0.53) | ALDH1A1MAPK1KMT2AUSP2GAA | |
| SCHEMBL3759815 | 0.66 | LMNA (0.46) | ALDH1A1POLBGLAKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | ALDH1A1 1031/4885POLB 4177/4885MAPK1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.